Advertisement

Managing high-risk CLL during transition to a new treatment era: stem cell transplantation or novel agents?

Peter Dreger, Johannes Schetelig, Niels Andersen, Paolo Corradini, Michel van Gelder, John Gribben, Eva Kimby, Mauricette Michallet, Carol Moreno, Stephan Stilgenbauer and Emili Montserrat on behalf of the European Research Initiative on CLL (ERIC) and the European Society for Blood and Marrow Transplantation (EBMT)